Press Release

74Software to execute an internal legal reorganization to better support its portfolio company strategy

Paris, September 16, 2026 – 74Software (Euronext Paris: 74SW) announces an internal legal reorganization aimed at better aligning the Group’s corporate structure with its portfolio company strategy.

This internal reorganization follows the acquisition of Sopra Banking Software, now SBS, in September 2024 and the subsequent renaming of Axway Software as 74Software in December 2024. The Group now operates through two main enterprise software brands, Axway and SBS, within a portfolio company structure.

As part of this reorganization, 74Software SA will remain the listed parent company of the Group, overseeing strategy, capital allocation, portfolio management and governance across its portfolio of software businesses. Axway’s French operating activities, currently housed within 74Software SA, as opposed to the Group’s other business activities, which are organized as subsidiaries, will be transferred to Axway SAS, a wholly owned and currently inactive French subsidiary of 74Software SA.

This internal legal reorganization is intended to improve the clarity of the Group’s structure by more clearly distinguishing 74Software SA’s role as the listed parent company overseeing the Group’s software portfolio from the operating entities dedicated to the Group’s business activities worldwide. It also provides a clearer and more flexible framework to support the Group’s future development and the potential integration of additional software businesses over time.

The transaction will be carried out through a contribution of the assets and liabilities relating to Axway’s French operating activities to Axway SAS. In consideration for this contribution, made at book value, Axway SAS will issue new shares to 74Software SA. The transaction will not involve any cash consideration.

This reorganization is a purely internal operation. It does not modify the Group’s strategy, consolidated scope, shareholder structure, stock market listing, governance or financial objectives. It is also not expected to have any impact on the day-to-day conduct of Axway’s operations, customer relationships, product roadmap or employee working conditions.

The employee representative body consultation process has been completed. The completion of this reorganization remains subject to confirmation by the AMF that no buyout offer is required under Article 236-6 of its General Regulation.

Subject to this confirmation and the final corporate steps, the transaction is expected to be completed before the end of October 2026, with retrospective accounting and tax effect from January 1, 2026.

About 74Software

74Software is an enterprise software group founded through the combination of Axway and SBS – independently operated leaders with unique experience and capabilities to deliver mission-critical software for a data driven world. A pioneer in enterprise integration solutions for 25 years, Axway supports major brands and government agencies around the globe with its core line of MFT, B2B, API, and Financial Accounting Hub products. SBS empowers banks and financial institutions to reimagine tomorrow’s digital experiences with a composable cloud-based architecture that enables deposits, lending, compliance, payments, consumer, and asset finance services and operations to be deployed worldwide. 74Software serves more than 12,000 companies, including over 1,500 financial service customers. To learn more, visit 74Software.com.

Contacts – Investor Relations:

Arthur Carli – +33 (0)1 47 17 24 65 – acarli@74software.com
Chloé Chouard – +33 (0)1 47 17 21 78 – cchouard@74software.com

Get the latest 74Software IR updates in your inbox by subscribing to our mailing list here.

Attachment

Earnings for the first half of 2026 September 16, 2026  

Revenue: 1,644 million euros, +8% at constant scope and exchange rates.

Net income, Group share: 54 million euros. compared with 163 million euros in the first half of 2025.

Exceptional interim dividend of 380 euros per share.

First-half 2026 results

Compagnie de l’Odet’s Board of Directors met on September 16, 2026 to approve the financial statements for the first half of 2026.

Revenue amounted to 1,644 million euros, an increase of 8% at constant scope and exchange rates:

  • Bolloré Energy: 1,467 million euros, +9% amid a general trend of rising prices linked to the conflict in the Middle East, despite a decline in volumes sold (-10%);
  • Industry: 156 million euros, +1%, marking a slight increase on the first half of 2025, driven by growth in Films activities (higher volumes in dielectric films and packaging) and Systems activities, despite a decline in Blue activities;
  • Other: 21 million euros, -6%, reflecting a decline in real estate revenue, and a decrease of 34 million euros on a reported basis, primarily attributable to the exit of Ovrsea from the scope of consolidation in December 2025 following its merger with Fusalpes.

On a reported basis, revenue increased by 6%, after a negative scope effect of -34 million euros (primarily related to the exit of Ovrsea from the scope of consolidation) and a positive foreign exchange effect of +1 million euros.

Adjusted operating income (EBITA (1)) was €97 million, down -20% on the first half of 2025.

  • Bolloré Energy (2): 47 million euros, up 77% against a backdrop of high prices, driven by positive stock effects and strong performance of distribution in France and Germany;
  • Communications (3) : 184 million euros, down, primarily due to lower contributions from Groupe Canal+
    (-21 million euros) and UMG (-6 million euros);
  • Industry (4): -42 million euros, a reduction in losses of 10 million euros compared with the first half of 2025, with Blue Solutions focusing on research into new-generation batteries;
  • Other: -93 million euros, an increase in personnel costs and a decrease in real estate revenue, resulting from the significant asset disposals carried out in recent years. 

Net financial income was 45 million euros, compared with 96 million euros in the first half of 2025, due to lower interest rates and a fall in the dividends received from the Socfin Group.

The net income from equity-accounted non-operating companies was 6 million euros, after breaking even in the first half of 2025, due to the increase in the share of Compagnie de l’Étoile des Mers’ net income. Since the end of 2024, this item has no longer included the share of net income from Socfin Group.

After taking into account -28 million euros in taxes (compared with -11 million euros in the first half of 2025), consolidated net income came to 96 million euros, compared with 257 million euros in the first half of 2025.

Net income Group share amounted to 54 million euros, compared with 163 million euros in the first half of 2025.

Shareholders’ equity totalled 20,017 million euros, compared with 21,089 million euros as at December 31, 2025, down -1,072 million euros, mainly due to dividends paid to minority shareholders (-1,190 million euros) and the acquisition of Bolloré SE shares (-253 million euros), despite the change in the fair value of the securities held by the Group (+333 million euros).

Group shareholders’ equity came to 13,269 million euros, compared with 12,793 million euros as at December 31, 2025.

As at June 30, 2026, Compagnie de l’Odet had a net cash position of 3,658 million euros, compared with 5,126 million euros at the end of 2025. The fall of -1,468 million euros includes in particular the payment of dividends to minority shareholders (-1,190 million euros) and acquisitions of minority interests for -253 million euros.

At the end of June 2026, Compagnie de l’Odet had 7 billion euros in cash and cash and confirmed lines.

Main transactions

Compagnie de l’Odet

  • On June 25, 2026, the company received an exceptional dividend of 1.5 euros per share from Bolloré SE, representing 3.1 billion euros.
  • Since the beginning of 2026, Compagnie de l’Odet has acquired 89 million Bolloré SE shares at a unit price of 4.57 euros (representing 3.2% of the share capital), for a total amount of 409 million euros, including 15 million shares held by subsidiaries of Bolloré SE, for 81 million euros, as part of the simplification of the Group’s structure.
  • In 2026, Compagnie de l’Odet acquired 15.7 million shares in Canal+ (1.58% of the share capital), at an average unit price of 2.53 pounds sterling, corresponding to a total amount of 40 million pounds sterling (equivalent to

46 million euros), completing the shares acquired in 2025. In total, Compagnie de l’Odet holds nearly 48 million shares representing 4.8% of the share capital, for an amount of 107 million pounds sterling (equivalent to 127 million euros).

Compagnie de l’Étoile des Mers

  • Compagnie de l’Étoile des Mers, a 51% subsidiary of Bolloré Participations SE and in which Compagnie de l’Odet holds 49%, acquired a stake in Havas N.V.. Compagnie de l’Étoile des Mers holds 22.6% of Havas N.V. for an investment of 347 million euros, representing a price per share of 15.5 euros. In addition, Bolloré SE still owns 30.44% of Havas N.V. directly and Compagnie de l’Odet 0.6%.

Vivendi spin-off

  • On April 22, 2025, following proceedings by the Luxembourg company CIAM Fund, the Paris Court of Appeal overturned a decision by the AMF on November 13, 2024, insofar as it had found that Bolloré SE did not control Vivendi SE within the meaning of article L. 233-3 of the French Commercial Code.
  • On July 18, 2025, pursuant to the Court of Appeal’s ruling of April 22, 2025, the AMF ruled that a public tender offer to delist the shares of Vivendi SE had to be filed within a period of six months. The offer would not close until the Court of Cassation had handed down its ruling on the appeals against the Paris Court of Appeal’s decision of April 22, 2025. On July 28, 2025, Bolloré SE decided to appeal to the Paris Court of Appeal against the AMF’s decision of July 18; the annulment of that decision was confirmed by the same court on April 9, 2026, as a result of the reversal of the April 22, 2025 judgment, as described below.
  • On November 28, 2025, the Court of Cassation overturned the ruling of April 22, 2025 to the extent it had ruled that Vivendi SE was controlled by Bolloré SE within the meaning of Article L. 233-3, I, 3° of the French Commercial Code on the grounds that the Court of Appeal had violated this provision and referred the case to the Paris Court of Appeal otherwise constituted. The hearing for oral arguments took place on May 22, 2026.
  • On July 8, 2026, the Paris Court of Appeal, sitting as an extended bench, dismissed all of CIAM Fund’s claims. The Court held that Vivendi SE could not be regarded as being controlled by Bolloré SE within the meaning of subsections 3° and 4° of Article L.233‑3 I of the French Commercial Code, and that the existence of control through concerted action, within the meaning of Article L.233‑3 III, was likewise not established. CIAM Fund was ordered to pay a total of €350,000 under Article 700 of the French Code of Civil Procedure, including €200,000 to Bolloré SE.
  • CIAM Fund has decided to lodge an appeal before the Cour de Cassation against the ruling by the Paris Court of Appeal dated July 8, 2026.

Bluebus/Blue Solutions

  • On September 8, Bolloré SE announced a project to discontinue the production of electric buses, which may affect 74 positions. In a French market that has been less dynamic than expected, marked by intense competition and significant pricing pressure, Bluebus is not large enough to compete with other players in the sector. After years of actively searching for solutions and despite the efforts made to adapt its business model, the company determined that the necessary conditions were no longer present. An offer has been made by a European industrial company to acquire certain assets, reducing the number of potential job losses.
  • Bolloré SE also announced a strategic refocusing of Blue Solutions on fourth‑generation battery development, which may affect 41 positions.

Exceptional interim dividends

Following the distribution by Bolloré SE in June 2026 of an exceptional dividend of €4.2 billion, and in accordance with the announcement made in its press release dated March 17, 2026, Compagnie de l’Odet’s Board of Directors has decided today to pay an exceptional interim dividend of €2.5 billion, which will be paid on September 29, 2026. The companies that directly and indirectly control Compagnie de l’Odet (Sofibol, Financière V and Omnium Bolloré) also decided today to pay exceptional interim dividends corresponding to the majority of the amount of the interim dividend received.
As a result of the distribution of these exceptional interim dividends, Bolloré SE and its subsidiaries will receive a total amount of approximately €2 billion. These subsidiaries include Compagnie du Cambodge, Financière Moncey and Société Industrielle et Financière de l’Artois. These three companies will meet on September 18 and be called upon to decide respectively the payment of exceptional interim dividends of €13 per Compagnie du Cambodge share (€789 million), €14 per Financière Moncey share (€261 million) and €650 per Société Industrielle et Financière de l’Artois share (€173 million). In case of favourable decisions, the payment of these interim payments by these three companies should take place in the first half of October 2026. New announcements will be made regarding the decisions that are taken on 18 September 2026.

Consolidated key figures

(in millions of euros) H1 2026 H1 2025 Change
Revenue 1,644 1,547 6%
EBITDA (1) 131 136  
Depreciation and provisions (34) (15)  
Adjusted operating income (EBITA (1)) 97 121 (20%)
Amortization resulting from PPAs and other items not included in EBITA(1) (24) 38  
EBIT 73 159  
o/w equity- accounted operating companies   162 247  
Financial income 45 96  
Share of the net income of equity-accounted non-operating companies 6 0  
Taxes (28) (11)  
Income from discontinued or held for sale activities – 14  
Net income 96 257 €(161)m
Net income, Group share 54 163  
Minority interests 41 94  
       
(in millions of euros) 06/30/2026 12/31/2025 Change    
Shareholders’ equity 20,017 21,089 (1,072)
    Of which Group share 13,269 12,793 476
Net debt / (Net Cash) (3,658) (5,126) 1,468
Gearing (2) n.a. n.a.  

(1)  See glossary.
(2)  Gearing: ratio of net debt to equity.

Change in revenue by activity

(in millions of euros) H1 2026 H1 2025 Reported Organic  
      growth growth  
Bolloré Energy 1,467 1,337 10% 9%  
Industry 156 156 0% 1%  
Other (Agricultural assets, Holding and others) 21 54 (62%) (6%)  
Total 1,644 1,547 6% 8%  

Change in revenue by quarter

(in millions of euros)            Q1         Q2  
  2026 2025 organic 2025 2026 2025 organic 2025

Bolloré Energy 731 678 675 736 663 661
Industry 74 77 78 82 78 78
Other (Agricultural assets, Holding and others) 10 11 28 11 10 26
Total 815 766 782 829 751 765

Adjusted operating income (EBITA)

(in millions of euros) H1 2026 H1 2025 Reported growth
Bolloré Energy (1) 47 27 77%
Communications 184 210 (12%) 
UMG (2) 112 118  
Canal+ (2) 27 48  
Louis Hachette Group (2) 6 7  
Havas (2) 26 23  
Vivendi (2) 13 14  
Industry (1) (42) (52) 20%
Other (Agricultural assets, Holding and others) (93) (63) (47%)
EBITA 97 121 (20%)

(1)  Before Group costs.
(2)  Operating companies accounted for using the equity method.

A detailed presentation of the results of its subsidiary Bolloré SE is available at www.bollore.com.
The limited review procedures for the 2026 interim consolidated financial statements have been performed, and the certification report will be issued after verification of the interim management report.

Group shareholder structure as of June 30, 2026

See the organization chart in the PDF press release

Comparability of financial statements

  • Performance indicators
    • At June 30, 2026, Compagnie de l’Odet has not changed the definition of its performance indicators, particularly EBITA, which are comparable to those at June 30, 2025. EBITA and operating income data are presented before Group expenses.
  • Trend in the main currencies
 Average rate 06/30/2026 06/30/2025 Change
USD 1.17 1.09 7%
GBP 0.87 0.84 3%
CHF 0.92 0.94 (2%)
CAD 1.61 1.54 4%
INR 108.51 94.14 15%

Glossary

  • Organic growth: at constant scope and exchange rates.
  • Adjusted operating income (EBITA): operating income before the amortization of intangible assets related to business combinations (PPA: purchase price allocation), the impairment of positive and negative goodwill arising on business combinations, and other intangible assets relating to disputes with shareholders or concerning businesses no longer operated by the Group.
  • EBITDA: earnings before interest, taxes, depreciation and amortization.
  • Net financial debt / Net cash position: sum of borrowings at amortized cost, less cash and cash equivalents, cash management financial assets and net derivative financial instruments (assets or liabilities) with net financial debt as their underlying asset, as well as cash deposits backing borrowings.

The non-GAAP measures defined above should be considered as additional information that does not replace GAAP measures of operating and financial performance; Compagnie de l’Odet considers them to be relevant indicators of the Group’s operating and financial performance. Other companies may define and calculate these indicators differently. The indicators used by Compagnie de l’Odet may therefore not be directly comparable with those of other companies.

The percentage changes shown in this document are calculated in relation to the same period of the previous fiscal year, unless otherwise stated. Due to rounding, in this presentation, the sum of some data may not correspond exactly to the calculated total, and the percentage may not correspond to the calculated variation.


(1) See glossary.
(2) Before Group costs.

(3) Operating companies accounted for using the equity method.
(4) Before Group costs.

Attachment

First-half 2026 results September 16, 2026  

Revenue: 1,644 million euros, +8% at constant scope and exchange rates.

Adjusted operating income (EBITA (1) (2)): 104 million euros, compared with 123 million euros in the first half of 2025.

Net income: 133 million euros, compared with 242 million euros in the first half of 2025.

Net income, Group share: 132 million euros.

Value of the portfolio of listed securities as at June 30, 2026: 9,232 million euros. As at September 14, 2026, the value stood at 7,943 million euros, reflecting the sharp decline in UMG’s stock price.

Net cash position: 1,447 million euros as at June 30, 2026, compared with 5,619 million euros as at December 31, 2025, following the payment by Bolloré SE of dividends (4,215 million euros in exceptional dividend and 169 million euros representing the balance of the ordinary dividend).

Exceptional interim dividends from Compagnie de l’Odet (2.5 billion euros) and the companies that control it.

First-half 2026 results

Bolloré’s Board of Directors met on September 16, 2026 to approve the financial statements for the first half of 2026.

Revenue amounted to 1,644 million euros, an increase of 8% at constant scope and exchange rates:

 Bolloré Energy: 1,467 million euros, +9% amid a general trend of rising prices linked to the conflict in the Middle East, despite a decline in volumes sold (-10%);

  • Industry: 156 million euros, +1%, marking a slight increase on the first half of 2025, driven by growth in Films activities (higher volumes in dielectric and packaging films) and Systems activities, despite a decline in Blue activities;
  • Other: 21 million euros, -6%, reflecting a decline in real estate revenue, and a decrease of 34 million euros on a reported basis, primarily attributable to the exit of Ovrsea from the scope of consolidation in December 2025 following its merger with Fusalpes.

On a reported basis, revenue increased by 6%, after a negative scope effect of -31 million euros (primarily related to the exit of Ovrsea from the scope of consolidation) and a positive foreign exchange effect of +1 million euros.

Adjusted operating income (EBITA (3)) was €104 million, down -15 % on the first half of 2025.

 Bolloré Energy (4): 47 million euros, up 77% against a backdrop of high prices, driven by positive stock effects and strong performance of distribution in France and Germany;

  • Communications (5): 181 million euros, down, primarily due to lower contributions from Groupe Canal+ (-19 million euros) and UMG (-5 million euros);
  • Industry (4): -42 million euros, a reduction in losses of 10 million euros compared with the first half of 2025, with Blue Solutions focusing on research into new-generation batteries;
  • Other: -82 million euros, an increase in personnel costs and a decrease in real estate revenue, resulting from the significant asset disposals carried out in recent years. 

 Net financial income was 64 million euros, compared with 95 million euros in the first half of 2025, due to lower interest rates and a fall in the dividends received from the Socfin Group.

The net income from equity-accounted non-operating companies remained broadly stable at -1 million euros. Since the end of 2024, this item has no longer included the share of net income from Socfin Group.

After taking into account -12 million euros in taxes (compared with -10 million euros in the first half of 2025), consolidated net income came to 133 million euros, compared with 242 million euros in the first half of 2025.

Net income Group share amounted to 132 million euros, compared with 240 million euros in the first half of 2025.
  

Shareholders’ equity totaled 20,803 million euros, compared with 24,427 million euros as at December 31, 2025, down -3,624 million euros, primarily due to dividends paid (4,387 million euros, including 4,215 million euros in exceptional dividends) despite an increase in the net change in the fair value of securities held (driven mainly by the increase in Compagnie de l’Odet’s share price) and the sale of Bolloré SE treasury shares.

Group shareholders’ equity came to 20,596 million euros, compared with 24,211 million euros as at December 31, 2025.

As at June 30, 2026, the Bolloré Group had a net cash position of 1,447 million euros, compared with 5,619 million euros at the end of 2025. The fall of -4,172 million euros includes the payment of the exceptional dividend in June 2026.

At end-June 2026, the Bolloré Group had 3.6 billion euros in cash and cash and confirmed credit lines.

Main transactions

Bolloré SE

 Since the beginning of 2026, Bolloré SE has sold 10 million Vivendi SE shares (representing 1% of the share capital) at a unit price of 2.2 euros, for a total of 22 million euros.

  • On July 6, 2026, Vivendi canceled 17.7 million shares. Following this cancellation, the Bolloré Group’s stake stands at 29.2%.

Compagnie de l’Odet

 Since the beginning of 2026, Compagnie de l’Odet has acquired 89 million Bolloré SE shares at a unit price of 4.57 euros (representing 3.2% of the share capital), for a total amount of 409 million euros, including 15 million shares held by subsidiaries of Bolloré SE, for 81 million euros, as part of the simplification of the Group’s structure.

  • In 2026, Compagnie de l’Odet acquired 15.7 million shares in Canal+ (1.58% of the share capital), at an average unit price of 2.53 pounds sterling, corresponding to a total amount of 40 million pounds sterling (equivalent to 46 million euros), completing the shares acquired in 2025. In total, Compagnie de l’Odet holds nearly 48 million shares representing 4.8% of the share capital, for an amount of 107 million pounds sterling (equivalent to 127 million euros).

Compagnie de l’Étoile des Mers

  • Compagnie de l’Étoile des Mers, a 51% subsidiary of Bolloré Participations SE and in which Compagnie de l’Odet holds 49%, acquired a stake in Havas N.V.. Compagnie de l’Étoile des Mers holds 22.6% of Havas N.V. for an investment of 347 million euros, representing a unit price of 15.5 euros. In addition, Bolloré SE still owns 30.44% of Havas N.V. directly and Compagnie de l’Odet 0.6%.

Vivendi spin-off

  • On April 22, 2025, following proceedings by the Luxembourg company CIAM Fund, the Paris Court of Appeal overturned a decision by the AMF on November 13, 2024, insofar as it had found that Bolloré SE did not control Vivendi SE within the meaning of article L. 233-3 of the French Commercial Code.  
  • On July 18, 2025, pursuant to the Court of Appeal’s ruling of April 22, 2025, the AMF ruled that a public tender offer to delist the shares of Vivendi SE had to be filed within a period of six months. The offer would not close until the Court of Cassation had handed down its ruling on the appeals against the Paris Court of Appeal’s decision of April 22, 2025. On July 28, 2025, Bolloré SE decided to appeal to the Paris Court of Appeal against the AMF’s decision of July 18; the annulment of that decision was confirmed by the same court on April 9, 2026, as a result of the reversal of the April 22, 2025 judgment, as described below.
  • On November 28, 2025, the Court of Cassation overturned the ruling of April 22, 2025 to the extent it had ruled that Vivendi SE was controlled by Bolloré SE within the meaning of Article L. 233-3, I, 3° of the French Commercial Code on the grounds that the Court of Appeal had violated this provision and referred the case to the Paris Court of Appeal otherwise constituted. The hearing for oral arguments took place on May 22, 2026.
  • On July 8, 2026, the Paris Court of Appeal, sitting as an extended bench, dismissed all of CIAM Fund’s claims. The Court held that Vivendi SE could not be regarded as being controlled by Bolloré SE within the meaning of subsections 3° and 4° of Article L.233‑3 I of the French Commercial Code, and that the existence of control through concerted action, within the meaning of Article L.233‑3 III, was likewise not established. CIAM Fund was ordered to pay a total of €350,000 under Article 700 of the French Code of Civil Procedure, including €200,000 to Bolloré SE.
  • CIAM Fund has decided to lodge an appeal before the Cour de Cassation against the ruling by the Paris Court of Appeal dated July 8, 2026.

Bluebus/Blue Solutions

  • On September 8, Bolloré SE announced a project to discontinue the production of electric buses, which may affect 74 positions. In a French market that has been less dynamic than expected, marked by intense competition and significant pricing pressure, Bluebus is not large enough to compete with other players in the sector. After years of actively searching for solutions and despite the efforts made to adapt its business model, the company has determined that the necessary conditions are no longer present. An offer has been made by a European industrial company to acquire certain assets, reducing the number of potential job losses.
  • Bolloré SE also announced a strategic refocusing of Blue Solutions on fourth‑generation battery development, which may affect 41 positions

Exceptional interim dividends

Following the distribution by Bolloré SE in June 2026 of an exceptional dividend of €4.2 billion, and in accordance with the announcement made in its press release dated March 17, 2026, Compagnie de l’Odet’s Board of Directors has decided today to pay an exceptional interim dividend of €2.5 billion, which will be paid on September 29, 2026. The companies that directly and indirectly control Compagnie de l’Odet (Sofibol, Financière V and Omnium Bolloré) also decided today to pay exceptional interim dividends corresponding to the majority of the amount of the interim dividend received.
As a result of the distribution of these exceptional interim dividends, Bolloré SE and its subsidiaries will receive a total amount of approximately €2 billion. These subsidiaries include Compagnie du Cambodge, Financière Moncey and Société Industrielle et Financière de l’Artois. These three companies will meet on September 18 and be called upon to decide respectively the payment of exceptional interim dividends of €13 per Compagnie du Cambodge share (€789 million), €14 per Financière Moncey share (€261 million) and €650 per Société Industrielle et Financière de l’Artois share (€173 million). In case of favourable decisions, the payment of these interim payments by these three companies should take place in the first half of October 2026. New announcements will be made regarding the decisions that are taken on 18 September 2026.

Consolidated key figures

(in millions of euros) H1 2026 H1 2025 Change
Revenue 1,644 1,547 6%
EBITDA (1) 138 138  
Depreciation and provisions (34) (15)  
Adjusted operating income (EBITA (1)) 104 123 (15%)
Amortization resulting from PPAs and other items not included in EBITA(1) (22) 21  
EBIT 82 144  
o/w equity- accounted operating companies   160 224  
Financial income 64 95  
Share of the net income of equity-accounted non-operating companies (1) (1)  
Taxes (12) (10)  
Income from discontinued or held for sale activities – 14  
Net income 133 242 €(108)m
Net income, Group share 132 240  
Minority interests 1 1  
       
(in millions of euros) 06/30/2026 12/31/2025 Change   
Shareholders’ equity 20,803 24,427 (3,624)
    Of which Group share 20,596 24,211 (3,615)
Net debt / (Net Cash) (1,447) (5,619) (4,172)
Gearing (2) n.a. n.a.  

(1)  See glossary.
(2)  Gearing: ratio of net debt to equity.

  
Change in revenue by activity

(in millions of euros) H1 2026 H1 2025 Reported Organic  
      growth growth  
Bolloré Energy 1,467 1,337 10% 9%  
Industry 156 156 0% 1%  
Other (Agricultural assets, Holding and others) 21 55 (61%) (6%)  
Total 1,644 1,547 6% 8%  

Change in revenue by quarter

(in millions of euros)            Q1 Q2  
  2026 2025 organic 2025 2026 2025 organic 2025

 

Bolloré Energy 731 678 675 736 663 661
Industry 74 77 78 82 78 78
Other (Agricultural assets, Holding and others) 10 12 29 11 11 26
Total 815 766 782 829 751 765

Adjusted operating income (EBITA)

(in millions of euros) H1 2026 H1 2025 Reported growth
Bolloré Energy (1) 47 27 77%
Communications 181 203 (11%) 
UMG (2) 112 117  
Canal+ (2) 24 44  
Louis Hachette Group (2) 6 6  
Havas (2) 26 23  
Vivendi (2) 12 13  
Industry (1) (42) (52) 20%
Other (Agricultural assets, Holding and others) (82) (55) (50%)
EBITA 104 123 (15%)

(1)  Before Group costs.
(2)  Operating companies accounted for using the equity method.

A detailed presentation of the income is available on www.bollore.com.
The limited review procedures for the 2026 interim consolidated financial statements have been performed, and the certification report will be issued after verification of the interim management report.

  

Portfolio of listed securities

  At 06/30/2026   At 09/14/2026   Change in prices since 01/01/2026 (%)(3)

 

In millions of euros Price (€) Stock market capitalization (%) held Market value   Price (€) Market value  
                   
Communications (*):                  
Universal Music Group 18.3 33,700 18.4% 6,197   14.8 5,000   (33%)
Groupe Canal+ £2.4 2,813 30.4% 856   £2.5 894   (5%)
Louis Hachette Group 1.7 1,733 30.4% 527   1.7 523   11%
Havas Group 17.1 1,691 30.4% 515   18.2 549   7%
Vivendi 2.2 2,193 28.8% 631   1.6 452   (34%)
                   
Other:                  
Socfin Group (1)       310     301   n.a.
Rubis 30.7 3,175 6.0% 190   35.5 220   11%
Other       5     4    
                   
Total       9,232     7,943    
Total dividends received from shareholdings in H1 2026(2) 198          

As at June 30, 2026, the portfolio was valued at 9.2 billion euros, down 13% on December 31, 2025.

(*) These shareholdings are accounted for using the equity method in the Group’s financial statements.

(1)   Interests in Socfinaf, Socfinasia and Socfin (of which 160 million euros for Socfin at delisted value).

(2)   Including UMG (95 million euros), Groupe Canal+ (6 million euros), Havas Group (24 million euros), Louis Hachette Group (18 million euros), and Vivendi (12 million euros).

(3)   As at September 14, 2026.

Appendix

Equity-accounted Companies and portfolio of listed and unlisted shareholdings

In millions of euros At 06/30/2026 At 12/31/2025
  Percentage of ownership * Net book
value
Percentage of ownership * Net book
value
Equity-accounted companies   10,505.2   10,590.0
UMG 18.39 7,938.6 18.43 8,015.5
Canal+ 30.43 811.5 30.43 804.9
Havas Group 30.44 544.9 30.44 531.5
Louis Hachette Group 30.43 305.5 30.43 317.0
Vivendi 28.78 833.9 30.44 850.6
Other   70.8   70.4
Total   10,505.2   10,590.0
         
In millions of euros At 06/30/2026 At 12/31/2025
  Percentage of ownership * Net book
value
Percentage of ownership * Net book
value
Listed shareholdings   3,777.1   3,510.9
Compagnie de l’Odet 35.83 3,431.1 35.83 3,158.1
Rubis 6.00 190.3 6.01 198.8
Socfinasia 22.25 110.8 22.25 109.0
Socfinaf 8.60 39.9 8.60 37.1
Other listed shareholdings   5.0   7.9
Unlisted shareholdings   4,559.5   4,220.6
Sofibol 48.95 2,450.8 48.95 2,260.4
Financière V 49.69 1,275.2 49.69 1,175.9
Omnium Bolloré 49.84 644.4 49.84 594.1
Other unlisted shareholdings   189.1   190.2
Total   8,336.6   7,731.5

(*) Bolloré SE’s consolidated percentage interest

Shareholder structure of the Bolloré Group as of June 30, 2026

See the organization chart in the PDF press release

Comparability of financial statements

  • Performance indicators
    • At June 30, 2026, the Bolloré Group had not changed the definition of its performance indicators, particularly EBITA, which were comparable to those at June 30, 2025. EBITA and operating income data are presented before Group expenses.
  • Changes in the main currencies
 Average rate 06/30/2026 06/30/2025 Change
USD 1.17 1.09 7%
GBP 0.87 0.84 3%
CHF 0.92 0.94 (2%)
CAD 1.61 1.54 4%
INR 108.51 94.14 15%

Glossary

  • Organic growth: at constant scope and exchange rates.
  • Adjusted operating income (EBITA): operating income before the amortization of intangible assets related to business combinations (PPA: purchase price allocation), the impairment of positive and negative goodwill arising on business combinations, and other intangible assets relating to disputes with shareholders or concerning businesses no longer operated by the Group.
  • EBITDA: earnings before interest, taxes, depreciation and amortization.
  • Net financial debt / Net cash position: sum of borrowings at amortized cost, less cash and cash equivalents, cash management financial assets and net derivative financial instruments (assets or liabilities) with net financial debt as their underlying asset, as well as cash deposits backing borrowings.

The non-GAAP measures defined above should be considered as additional information that does not replace GAAP measures of operating and financial performance; Bolloré considers them to be relevant indicators of the Group’s operating and financial performance. Other companies may define and calculate these indicators differently. The indicators used by Bolloré may therefore not be directly comparable with those of other companies.

The percentage changes shown in this document are calculated in relation to the same period of the previous fiscal year, unless otherwise stated. Due to rounding, in this presentation, the sum of some data may not correspond exactly to the calculated total, and the percentage may not correspond to the calculated variation.
  


(1) See glossary.
(2) Including the contribution from UMG accounted for using the equity method for +181 million euros.
(3) See glossary.
(4) Before Group costs.

(5) Operating companies accounted for using the equity method.

Attachment

JCDecaux renews its advertising contract with Düsseldorf

Paris, 16 September 2026 – JCDecaux SE (Euronext Paris: DEC), the number one outdoor advertising company worldwide, announces that Wall GmbH, a subsidiary of JCDecaux, has been awarded the exclusive advertising contract for the 2m² format in Düsseldorf, the state capital of Germany’s largest federal state, North Rhine-Westphalia, following a competitive tender process. The contract covers the advertising rights on public space as well as at the bus and tram stops of the transport operator Rheinbahn.

Düsseldorf, the state capital, is one of Germany’s most important media hubs and, with around 620,000 inhabitants, the sixth-largest city in the country. Numerous media agencies and nationally significant advertisers are headquartered there. In addition, “Königsallee”, the city centre’s renowned shopping street, is one of Germany’s most exclusive retail destinations and attracts high purchasing power, making it particularly appealing to luxury brands. Securing these advertising rights is therefore of major strategic importance and further strengthens JCDecaux’s position – following its successful tender in Hamburg – as the premium outdoor advertising company in both the German and international market.

The new contract for the exclusive advertising rights in the 2m² format for the state capital of Düsseldorf and the Düsseldorf Rheinbahn network includes 965 bus shelters as well as 143 free-standing city information panels, featuring both analogue and digital advertising faces. The number of digital screens within these panels will increase from 125 to 175.

Jean-François Decaux, Co-Chief Executive Officer of JCDecaux, said: “We have enjoyed a partnership with Düsseldorf since 1984. In close collaboration with the city, we have been able to develop one of the most attractive digital advertising networks in Germany over the past few years, thereby creating a premium, high-reach offering for both our clients and Düsseldorf. Over the coming year, we will continue to expand our digital network in Düsseldorf to create additional efficient, data-optimised and targeted communication solutions for advertisers. We would like to thank the state capital and the transport operator Rheinbahn for their continued trust in our company.”

Key Figures for JCDecaux

  • 2025 revenue: €3,967.1m – H1 2026 revenue: €1,953.9m
  • N°1 Out-of-Home Media company worldwide
  • A daily audience of 850 million people in 78 countries
  • 1,105,906 advertising panels worldwide
  • Present in 3,895 cities with more than 10,000 inhabitants
  • 11,894 employees
  • JCDecaux is listed on the Eurolist of Euronext Paris and is part of the SBF 120 and CAC Mid 60 indexes
  • JCDecaux’s Group carbon reduction trajectory has been approved by the SBTi and the company has joined the Euronext Paris CAC® SBT 1.5° index
  • JCDecaux is recognised for its extra-financial performance in the CDP (A-List), MSCI (AAA), Sustainalytics (11.1), and has achieved Gold Medal status from EcoVadis
  • Member of the UN Global Compact since 2015 and of the RE100 since 2019
  • Leader in self-service bike rental scheme: pioneer in eco-friendly mobility
  • N°1 worldwide in street furniture (636,625 advertising panels)
  • N°1 worldwide in transport advertising with 154 airports and 257 contracts in metros, buses, trains and tramways (374,718 advertising panels)
  • N°1 in Europe for billboards (94,562 advertising panels worldwide)
  • N°1 in outdoor advertising in Europe (740,067 advertising panels)
  • N°1 in outdoor advertising in Asia-Pacific (168,815 advertising panels)
  • N°1 in outdoor advertising in Latin America (103,865 advertising panels)
  • N°1 in outdoor advertising in Africa (31,364 advertising panels)
  • N°2 in outdoor advertising in the Middle East (20,852 advertising panels)

For more information about JCDecaux, please visit jcdecaux.com.
Join us on X, LinkedIn, Facebook, Instagram and YouTube.

Communications Department: Clémentine Prat
+33 (0) 1 30 79 79 10 – clementine.prat@jcdecaux.com  

Investor Relations: Rémi Grisard
+33 (0) 1 30 79 79 93 – remi.grisard@jcdecaux.com

Attachment

EzyTrace Integrates Fertilizer Stock Tracking, Logistics Visibility and Modern Farming Intelligence

KUALA LUMPUR, Malaysia, Sept. 16, 2026 (GLOBE NEWSWIRE) — Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a Southeast Asia–anchored technology company focused on AI-powered enterprise solutions and digital transformation, today announced that its subsidiary, Tadaa Technology Sdn Bhd (“Tadaa”), has secured a US$52million strategic partnership agreement with E Agro Digital Sdn Bhd (“E Agro Digital”) to develop and deploy EzyTrace an advance AI-powered agricultural supply chain platform for Malaysia’s Ministry of Agriculture and Food Security. Tadaa is anticipated to recognize revenue from this engagement commencing Q4 2027.

Under the partnership agreement, Tadaa will provide artificial intelligence, data analytics capabilities and enterprise platform infrastructure, while E Agro Digital will supply specialized agricultural technology expertise and domain knowledge; the combined capabilities will address the Ministry’s requirements for real-time agricultural supply chain visibility, precision farming analytics, and integrated inventory management across Malaysia’s agricultural distribution network.

EzyTrace is designed to deliver end-to-end supply chain visibility and inventory accountability, providing the Ministry with real-time tracking of agricultural stock from warehouse to distribution point. The platform integrated GPS, IoT sensors and AI-driven analytics to enable automated inventory reconciliation, reduce manual data entry errors, and provide decision support capabilities for agricultural logistic optimization. The partnership includes precision agriculture capabilities designed to provide Malaysian farmers with actionable insights on crop health, irrigation optimization, fertilizer application timing, and pest management. These capabilities leverage AI-powered analytics on satellite and sensor date to improve resource allocation efficiency. Industry research (Mordor Intelligence, Global AI in Agriculture Market, 2026) indicates precision agriculture technologies have demonstrated measurable improvement in crop yield efficiency while reducing chemical input costs, a key priority for Malaysia’s agricultural modernization strategy.

“This partnership represents a significant milestone for Tadaa, demonstrating our ability deliver enterprise-scale AI solution to government agencies” said Sam Teo, Acting Chief Executive Officer of Treasure Global. “EzyTrace provides the Ministry with real-time supply chain visibility and opertional control across Malaysia’s agricultural distribution network. With an addressable market of over US$31billion in regional logistics services and approximately US$28.5billion in food and agriculture logistic alone, combined with APAC government AI investment expanding from US$40.88 billion in 2025 to an estimated US$490 billion in 2035, this engagement position Tadaa to pursue additional government digitalization opportunities across Southeast Asia. We expect this deployment to establish reference capability and targeting additional 2-3 additional government contract within the next 12-24 months” said Sam Teo, Acting Chief Executive Officer of Treasure Global.

The initiative comes amid rapid growth in the adoption of AI and precision technologies across the agriculture sector. According to Mordor Intelligence, the global AI in agriculture market is projected to grow from approximately US$3.11 billion in 2026 to approximately US$8.39 billion by 2031, a compound annual growth rate of approximately 22.0%, with Asia-Pacific recording the fastest regional growth as governments across the region invest in digital agriculture programs.

Treasure Global believes the collaboration strengthens its presence in public-sector AI and digital agriculture while positioning Tadaa to pursue additional opportunities in agricultural supply-chain management, AI-enabled resource planning and government digitalization, supporting the Company’s broader strategy of developing scalable technology-driven revenue opportunities.

About Treasure Global:
Treasure Global is a Malaysia-based technology solutions provider specializing in innovative platforms that drive digital transformation in retail and services. The Company’s flagship product is the ZCITY Super App, which integrates e-payment solutions with customer loyalty rewards to create a seamless online-to-offline user experience. As of March 31, 2026, ZCITY has attracted 2.71 million registered users, positioning Treasure Global as a key player in Malaysia’s digital economy. Treasure Global continuously leverages cutting-edge technologies, including artificial intelligence and data analytics, to enhance its platform’s capabilities across e-commerce, fintech, and other verticals.

Visit treasureglobal.org for more information.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company’s current expectations, assumptions, and projections about future events and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking statements typically include terminology such as “anticipates,” “believes,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” or similar expressions.

Factors that could cause actual results to differ materially include, without limitation, the ability of Tadaa and Eagro Digital to successfully design, deploy and maintain the EzyTrace platform; achieve anticipated operational benefits; meet project timelines and requirements; integrate AI, GPS, sensor and tracking technologies; maintain system reliability and cybersecurity; achieve adoption by government stakeholders and farmers; comply with applicable government procurement, data privacy and agricultural requirements; and respond to changes in technology, agricultural policies, market conditions and competition.

The forward-looking statements in this press release speak only as of the date hereof. The Company assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

CONTACT
Investor and media contact:
Investor Relations Team
Treasure Global
ir_us@treasureglobal.org

Series RIKB 38 0215 RIKS 50 0915
ISIN IS0000037265 IS0000037794
Maturity Date 02/15/2038 09/15/2050
Auction Date 09/18/2026 09/18/2026
Settlement Date 09/23/2026 09/23/2026
10% addition 09/22/2026 09/22/2026

On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bonds in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury bonds must be received by the Central Bank before 14:00 on the Settlement Date, and the Bonds will be delivered in electronic form on the same day. Article 6 of the General Terms of Auction for Treasury bonds applies for the right to purchase an additional 10%.

Further reference is made to the description of the Treasury bond and the General Terms of Auction for Treasury bonds on the Government Debt Management website.

For additional information please contact Oddgeir Gunnarsson, Government Debt Management, at +354 569 9635.

SHELTON, Conn., Sept. 16, 2026 (GLOBE NEWSWIRE) — Acme United Corporation (NYSE American: ACU) today announced Acme United’s Chairman and Chief Executive Officer Walter Johnsen will present at the Sidoti Small-Cap Conference being held virtually on Wednesday, September 23, 2026.

The Company’s presentation will begin at 12:15 PM ET on Wednesday, September 23 and can be accessed live here. Acme United will also participate in virtual one-on-ones with investors on the same day.

About Acme United
ACME UNITED CORPORATION is a leading worldwide supplier of innovative safety solutions and cutting technology to the school, home, office, hardware, sporting goods and industrial markets. Its leading brands include First Aid Only®, First Aid Central®, PhysiciansCare®, Pac-Kit®, Spill Magic®, Westcott®, Clauss®, DMT®, Med-Nap®, Elite First Aid® and My Medic®. For more information, visit www.acmeunited.com.

CONTACT: Paul G. Driscoll Acme United Corporation 1 Waterview Drive Shelton, CT 06484
    Phone: (203) 254-6060    

Suominen Corporation’s stock exchange release on September 16, 2026 at 6:30 p.m. (EEST)

Changes in the Suominen Leadership Team

As we continue to transform Suominen and strengthen our performance, we are further developing the capabilities and ways of working needed to execute our strategy and realize the full potential of our business.

To strengthen our strategic execution and the leadership needed to drive this change, we are making changes in the Suominen Leadership Team, effective September 17, 2026.

Eevaleena Mäki-Uuro, Senior Vice President, Commercial Excellence and Strategic Projects, has been appointed Chief Strategy and Transformation Officer (CSTO) and member of the Suominen Leadership Team. In her new role, Eeva will report to President and CEO Charles Héaulmé.

Eevaleena brings international experience in strategic and transformation projects from both management consulting and the process industry. Prior to Suominen, she worked in strategy, sustainability and business leadership roles at Huhtamäki. Her background also includes management consulting at Bain & Company.

“I’m pleased to welcome Eevaleena to our team. She has a significant track record in raising strategic programs, bringing people together, planning and executing complex cross-functional initiatives”, says Charles Héaulmé, President and CEO Suominen.

Anni Luoma, General Counsel, has been appointed Chief Legal Officer and member of the Suominen Leadership Team. In her new role, Anni will report to Charles Héaulmé.

Anni joined Suominen as Legal Counsel in 2022 and was promoted to General Counsel in 2024. Prior to Suominen, she worked at Neles, currently part of Valmet, as well as at Metso and Metso Outotec.

“Anni works effectively and closely with our leadership team and the Board of Directors on legal and compliance matters, and I am happy to welcome her to our team”, says Charles Héaulmé.

Suominen’s current Chief Strategy and Transformation Officer (previously also acting as Interim General Counsel) Marika Väkiparta has decided to leave the company to pursue other professional endeavors. She will continue with Suominen until the end of October 2026, focusing on strategic projects.

“Marika has played an important role in shaping and advancing Suominen’s transformation. Her contribution has been instrumental in establishing the direction and foundations for our Full Potential Program and in driving several strategic initiatives across the company. I would like to thank Marika for her commitment, leadership and contribution to Suominen. The work she has done provides a strong foundation for us to continue our transformation and improve our performance”, says Charles Héaulmé.

Suominen Leadership Team as of September 17, 2026:

  • Charles Héaulmé, President and CEO
  • Kimmo Raunio, Chief Financial Officer
  • Francois Guetat, Chief Operating Officer
  • Markku Koivisto, Chief Commercial and Technology Officer
  • Anni Luoma, Chief Legal Officer
  • Eevaleena Mäki-Uuro, Chief Strategy and Transformation Officer
  • Liisa Pursiheimo, Chief Human Resource Officer

SUOMINEN CORPORATION
Board of Directors

Further information:

Charles Héaulmé, President and CEO, tel. +358 10 214 3268

Distribution:

Nasdaq Helsinki
Key media
www.suominen.fi

About Suominen Corporation

Suominen manufactures nonwovens as roll goods for wipes and other applications. Our vision is to be the frontrunner for nonwovens innovation and sustainability. The end products made of Suominen’s nonwovens are present in people’s daily life worldwide. Suominen’s net sales in 2025 were EUR 412.4 million and we have almost 700 professionals working in Europe and in the Americas. Suominen’s shares are listed on Nasdaq Helsinki. Read more at www.suominen.fi.

Attachments

– Increased or Maintained Dividend for Over 33 Consecutive Years –

GREAT NECK, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) — One Liberty Properties, Inc. (NYSE: OLP) today announced that its Board of Directors declared a quarterly dividend on the Company’s common stock of $0.45 per share. The dividend is payable on October 6, 2026 to stockholders of record at the close of business on September 24, 2026, and represents One Liberty’s 135th consecutive quarterly dividend. One Liberty has increased or maintained its dividend for over 33 consecutive years.

About One Liberty Properties, Inc:

One Liberty is an industrial focused real estate investment trust organized in Maryland in 1982. The Company owns and operates a geographically diversified portfolio consisting primarily of industrial properties across the United States. Additional financial and descriptive information on One Liberty, its operations and its portfolio, is available on its website at: http://1liberty.com. Interested parties are encouraged to review One Liberty’s Annual Report on Form 10-K and the other reports it files with the Securities and Exchange Commission for additional information.

Contact:
One Liberty Properties
Investor Relations
Phone: (516) 466-3100
http://1liberty.com

LONDON and PHILADELPHIA, Sept. 16, 2026 (GLOBE NEWSWIRE) — Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, announces today that it has achieved clinical proof of mechanism for AVA6103, its next-generation controlled-release pre|CISION® peptide-drug conjugate (PDC) platform in the ongoing phase 1 FOCUS-01 trial.

Preliminary data from the Phase 1a trial of AVA6103 in patients with select solid tumors demonstrate proof of mechanism with two key findings:

  •  AVA6103 pre|CISION® controlled-release exatecan demonstrates a clean safety profile through the first three dose levels, including a payload dose level 50% higher than the maximum tolerated dose (MTD) of conventional exatecan, and
  •  The comparison of the preclinical modeled pharmacokinetic (PK) data and clinical trial PK data demonstrates an exceptional alignment through the first 3 dose levels with controlled release of exatecan evident in patients for days after dosing

The alignment of these critical datasets greatly increases our confidence that the safety profile, tumor selectivity and antitumor efficacy observed in the preclinical studies of AVA6103 will translate into the clinic.

The first head-to-head comparison of AVA6103 and Enhertu®, a marketed antibody drug conjugate (ADC) that targets HER2, demonstrates that AVA6103 shows better antitumor activity vs. Enhertu®, with deep and durable responses delivered by our dose dense regimen that has been applied in the FOCUS-01 trial.

Christina Coughlin, CEO of Avacta, commented:

“We are thrilled to report the proof of mechanism data with our first Next-Generation pre|CISION® molecule in the clinic, which continues to underscore the potential of our platform to make a significant difference to cancer patients. AVA6103 moved from candidate status to Investigational New Drug application in less than a year, and has now reached an initial clinical readout with excellent safety and PK data, showing it is performing exactly as expected from the data generated in our preclinical studies.  

“Our head-to-head comparison with the marketed ADC Enhertu® shows better activity in a HER2+ preclinical model even at low FAP levels, with the dose-dense regimen demonstrating advantages of AVA6103 over traditional dosing of ADCs.

“We continue our discussions with potential partners on the Next Gen assets and these data greatly increase our partnering position across the Next Gen platform. The FOCUS-01 trial continues to enroll patients into two parallel arms and we look forward to providing further updates as the trial progresses.

“With FAP expression in ~90% of solid tumors, these clinical findings provide a gateway for Avacta to link multiple payloads and access previously unaddressable markets.  This is a major inflection point for our Next Gen pre|CISION® platform, providing the opportunity for pipeline expansion to benefit patients and shareholders alike.”

Clinical Proof of Mechanism of AVA6103 in the FOCUS-01 Trial

Trial design and progress:

The FOCUS-01 Phase 1 clinical trial of AVA6103 is enrolling patients with locally advanced or metastatic disease with one of six indications, being: colorectal cancer, pancreatic ductal adenocarcinoma, gastric/gastroesophageal junction cancers, cervical cancer or small cell lung cancer. 

  • The first three dose levels have completed enrollment of patients (n=19) in two parallel arms with doses administered every two weeks (Q2W) or every three weeks (Q3W) and assessed for safety and tolerability, PK / pharmacodynamics (PD) and preliminary efficacy. The first three dose levels in the AVA6103 trial were 1.5 mg/m2, 3 mg/m2 and 4.5 mg/m2 to enable the comparison to both the Phase 1 trial of Enhertu® and conventional exatecan:
    • The first three dose levels are similar to the absolute payload dose levels in the published Enhertu® Phase 1 trial (Doi, et al. 2017);
    • Dose level 2 of AVA6103 is similar to the MTD of conventional exatecan (Rowinsky, et al. 2000); and
    • Dose level 3 represents an approximate 50% increase over this MTD of conventional exatecan.  

Safety, tolerability and PK data in the first three dose levels are presented.  Screening is ongoing for enrollment of patients into both the Q2W and Q3W arms at dose level 4.

Safety data
Patients in the FOCUS-01 trial were treated with escalating doses (1.5 mg/m2 to 4.5 mg/m2) and assessed for safety and tolerability. These data were compared with published data for Enhertu® (releasing a highly similar payload, deruxtecan) and with conventional exatecan administered in the standard regimen (once daily for five days).   

  • The safety profile of AVA6103-derived exatecan is highly favorable at the first three dose levels when compared with equivalent dosing of topoisomerase I inhibitors (Topo Ii) (conventional exatecan and Enhertu-derived deruxtecan), with minimal toxicity reported with AVA6103.
  • Notably, AVA6103 produced little toxicity at the equivalent and escalated doses of the MTD of conventional exatecan in heavily pretreated patients (Rowinsky et al. 2000) and at similar payload doses in the first three cohorts in the Phase 1 of Enhertu® (Doi et al. 2017). Relevant comparison data include:
    • Neutropenia: 0% with AVA6103, 22% with similar doses of Enhertu, and 64% at the MTD of conventional exatecan (equivalent to the 3 mg/m2 dose of AVA6103).
    • Thrombocytopenia: 5% (1/19) with AVA6103, 11% with Enhertu® and 43% with conventional exatecan;
    • Anemia: 16% (3/19) with AVA6103, 11% with similar doses of Enhertu® and 43% with conventional exatecan; and
    • Nausea and vomiting: 5% (1/19) with AVA6103, 44% with Enhertu® and 67% with exatecan (reported across all dose levels in this trial). 

Pharmacokinetic data

Patients were assessed for plasma PK properties across the first three dose levels of AVA6103 and compared to the corresponding dose levels of Enhertu®. 

  • As seen previously in preclinical models, the first three dose levels in the trial demonstrate rapid reduction in the plasma level of the PDC (AVA6103), with prolonged low-level release of both products of the cleavage reaction, the pre|CISION® peptide and released exatecan.
  • Given the very short half-life of the released peptide (2-3 hours) that was demonstrated in the AVA6000 program, and the detection of low levels of the released peptide from AVA6103 in the plasma up to 48 hours after dosing indicates that the PDC is being retained in the tumor in a ‘drug reservoir’ that is slowly being cleaved to release the peptide and exatecan, as this mechanism was designed to do.
  • The remarkable consistency of these results with predictive PK modeling based on preclinical studies greatly increase our confidence that AVA6103 is performing as intended, and that the robust preclinical data will translate to the clinic and support ongoing dose-escalation and efficacy evaluation in the Phase 1 trial.

Preclinical efficacy comparison with Enhertu®

  • The comparative efficacy of Enhertu® and AVA6103 was tested in a head-to-head format using a gastric cancer patient-derived xenograft model that is HER2+ and FAP+ (by IHC).
  • When tumors had grown to 100-200 mm3 in size, animals were randomized to receive either AVA6103 or Enhertu® at the preclinical dose with evidence of activity (Enhertu® x 1 or AVA6103 QWx3 dose dense regimen). 
  • Enhertu® treatment resulted in a slowed growth compared to vehicle control, with two animals demonstrating small tumor reductions and 1/6 with progression as best response.  In comparison, AVA6103 treatment resulted in deep and prolonged partial responses in 6/6 animals treated.  

Outlook

  • The design of the FOCUS-1 trial of AVA6013 and preclinical updates will be presented in Trials in Progress presentations at both the American Association of Cancer Research (AACR) Conference on Pancreatic Cancer, being held on September 25-28, 2026, and the European Society for Medical Oncology (ESMO) Congress, being held on October 23-27, 2026.
  • First efficacy data from the FOCUS-01 trial with AVA6103 is anticipated to be presented in H1 2027 – including data from clinical tumor biopsies which are anticipated to confirm AVA6103 is being retained in a ‘drug reservoir’ in the tumor, based on the preliminary Phase 1 data.
  • The selection of the payloads and data to support clinical candidate selection for the Dual Payload Next Gen Program (AVA6207) will be presented in Q4 2026.
  • Clinical data from the First Gen faridoxorubicin (AVA6000) program will also be presented in Q4 2026 at the ESMO Congress.

Enhertu® (trastuzumab deruxtecan; T-DXd) is a protease cleavable-linker ADC, approved for both breast cancer and gastric cancer indications (an AstraZeneca/Daiichi Sankyo product). Enhertu® is a registered trademark of Daiichi Sankyo Company, Limited and AstraZeneca.

Doi et al. 2017. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncology (2017). 18(11):1512-22. doi: 10.1016/S1470-2045(17)30604-6

Rowinsky et al. 2000. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. Journal of Clinical Oncology (2000). 18(17):3151-63. doi:10.1200/JCO.200.18.17.31

–Ends–

For further information from Avacta, please contact:

Avacta Group plc
Christina Coughlin, Chief Executive Officer
https://avacta.com/
via Cohesion Bureau
   
Strand Hanson Limited (Nominated Adviser)
James Harris / Chris Raggett / James Dance
www.strandhanson.co.uk
Zeus (Broker)
James Hornigold / George Duxberry / Dominic King
www.zeuscapital.co.uk
Cohesion Bureau
Communications / Media / Investors
Richard Jarvis
avacta@cohesionbureau.com

 

   

About Avacta – https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta’s innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.

Our pre|CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre|CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer. 

About FAP-Exd (AVA6103)

AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Next Generation innovative pre|CISION® controlled release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload. 

–Ends–

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.